| Volume 22, 2018 Articles |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
PreScription: 2017--Some Good Things Happened and Some Others
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 4
|
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies
Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 7-16
|
Pain: Systematic Review of Pharmacy Compounding of Pain Medication
Shawaqfeh Mohammad S, Harrington Catherine
|
Jan/Feb 2018
Pg. 19-24
|
The International Academy of Compounding Pharmacists: Government Affairs Lookback on 2017 Accomplishments and Look Ahead at 2018 Initiatives
Blankenship Cynthia
|
Jan/Feb 2018
Pg. 26-28
|
Basics of Compounding: Providing Pharmacy Services to Bariatric Surgery Patients
McElhiney Linda F
|
Jan/Feb 2018
Pg. 30-39
|
Sterile Basics of Compounding: Relationship Between Syringe Size and Dosing Accuracy
Kosinski Tracy M, Brown Michael C, Zavala Pedro J
|
Jan/Feb 2018
Pg. 41-46
|
Calculations
Stockton Shelly J
|
Jan/Feb 2018
Pg. 48
|
Glutamate and Aspartate Cardioplegia Additive Solution
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 50
|
Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 51
|
Metronidazole 50 mg/mL in Ora-Blend Suspension
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 52
|
Miconazole 10% in Recura Topical Cream
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 53
|
Naproxen 25 mg/mL in Oral Mix or Oral Mix SF
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 54
|
Penicillamine-D 50 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 55
|
Ranitidine 15 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 56
|
Sodium Citrate 9% Nasal Spray for Olfactory Disorders
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 57
|
Thalidomide 20 mg/mL in Ora-Plus and Ora-Sweet Suspension
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 58
|
Voriconazole 40-mg/mL Oral Suspension
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 59
|
Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing
Song Guiyun, Banov Daniel, Bassani August S
|
Jan/Feb 2018
Pg. 60-65
|
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
|
Jan/Feb 2018
Pg. 66-75
|
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection
Wu George, Powers Dan, Yeung Stanley, Chen Frank
|
Jan/Feb 2018
Pg. 76-85
|
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
|
Jan/Feb 2018
Pg. 86-94
|
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 92
|
Pharmacogenomics: Precision Pharmacy in 503A Compounding
Drummond Joseph, Bennet Daron, Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 95-107
|
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun
|
Mar/Apr 2018
Pg. 108-121
|
IACP Legislative/Regulatory Update: The International Academy of Compounding Pharmacists Testifies at U.S. House of Representatives' Energy & Commerce Health Subcommittee Pharmacy Compounding Hearing
Blankenship Cynthia
|
Mar/Apr 2018
Pg. 125-126
|
Quality Control: Lessons Learned from a Trimix Stability Study in a 503A Compounding Pharmacy
Rhoads Rick
|
Mar/Apr 2018
Pg. 129-134
|
Basics of Compounding: Compounding Microemulsions
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 137-143
|
Calculations
Stockton Shelly J
|
Mar/Apr 2018
Pg. 144
|
Clonidine Hydrochloride 10 mg/mL in Inorpha Solution
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 146
|
Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 147
|
Lamotrigine 1-mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 148
|
Levodopa and Carbidopa Rectal Suspension
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 149
|
Prochlorperazine Edisylate 0.5% Nasal Spray
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 150
|
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 151
|
Spironolactone 5-mg/mL in Suspendit Oral Suspension
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 152
|
Trilostane 5-mg/mL in Cod Liver Oil Suspension (Vet)
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 153
|
Evaluation and Comparison of Wound Healing Properties of an Ointment (AlpaWash) Containing Brazilian Micronized Propolis and Peucedanum ostruthium Leaf Extract in Skin Ulcer in Rats
Nani Marcel, Leone Andréia, Bom Vinícius Pedro, Buszinski Andrei Felipe, Oliveira de Souza Rebeca, Pinheiro Vanessa Alves, Danapoulos Panagiota, Swikidisa Rosita, Marquele-Oliveira Franciane, Cipriani Frade Marco Andrey, Berretta Andresa Aparecida, Nogueira Rodrigo José Lupatini
|
Mar/Apr 2018
Pg. 154-163
|
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
|
Mar/Apr 2018
Pg. 164-171
|
Topical Ketamine in the Treatment of Complex Regional Pain Syndrome
Durham Melissa J, Mekhjian Hovik S, Goad Jeffery A, Lou Mimi, Ding Michelle, Richeimer Steven H
|
Mar/Apr 2018
Pg. 172-175
|
PreScription: Influence and Sphere of Influence
Allen Loyd V Jr
|
May/Jun 2018
Pg. 180
|
Pitch Ointment: Applications in Scar and Wound Management
Kloesel Lawson, Carvalho Maria, Banov Fabiana
|
May/Jun 2018
Pg. 182-188
|
Establishing a Rationale for Compounding Hormone Replacement Therapy
Biundo Bruce
|
May/Jun 2018
Pg. 190-195
|
Case Report of a Human Papillomavirus Infection Treated with Green Tea Extract and Curcumin Vaginal Compounded Medications
Agbi Kelechi E, Hover Sara, Carvalho Maria
|
May/Jun 2018
Pg. 196-202
|
Your Presence is Needed at Compounders on Capitol Hill!
Blankenship Cynthia
|
May/Jun 2018
Pg. 204-205
|
Quality Control–Sterile Compounding: Analytical Methods. Density Determinations and Quality Control in Nonsterile and Sterile Compounding
Allen Loyd V Jr
|
May/Jun 2018
Pg. 206-217
|
Basics of Compounding–Nonsterile: Compounding Self-emulsifying Drug Delivery Systems and Other Self-emulsifying Lipid Formulations, Part 1
Allen Loyd V Jr
|
May/Jun 2018
Pg. 220-228
|
Calculations
Stockton Shelly J
|
May/Jun 2018
Pg. 230
|
Anhydrous Silicon Base Topical Gel Vehicle
Allen Loyd V Jr
|
May/Jun 2018
Pg. 232
|
Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2018
Pg. 233
|
Dorzolamide 2% Ophthalmic Solution
Allen Loyd V Jr
|
May/Jun 2018
Pg. 234
|
Gabapentin 100 mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
May/Jun 2018
Pg. 235
|
Pyrimethamine 2 mg/mL in Ora-Plus and Ora-Sweet Oral Suspension
Allen Loyd V Jr
|
May/Jun 2018
Pg. 236
|
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture
Allen Loyd V Jr
|
May/Jun 2018
Pg. 237
|
Simvastatin 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
May/Jun 2018
Pg. 238
|
Trimethoprim 20 mg/mL and Sulfadiazine 100 mg/mL in Suspendit Oral Suspension
Allen Loyd V Jr
|
May/Jun 2018
Pg. 239
|
Investigation of the Physical, Chemical, and Microbiological Stability of Oral Solutions Compounded with Herbals
Khokhlova Kateryna O, Zdoryk Oleksandr A
|
May/Jun 2018
Pg. 240-246
|
Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations
Visser J Carolina, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J
|
May/Jun 2018
Pg. 247-251
|
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Cote Brianna, Ross Bethany, Fortner Jeff, Rao Deepa
|
May/Jun 2018
Pg. 252-256
|
Trace Level Analysis of Airborne Hormone Particulates
Trimble John O, Hampton Shanna
|
May/Jun 2018
Pg. 257-263
|
Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension
|
May/Jun 2018
Pg. 263
|
PreScription: Factors Related to Drug Waste and Pharmacy Solutions
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 268
|
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Muller George, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
|
Jul/Aug 2018
Pg. 270-278
|
Compounding from a Pharmacy Student's Perspective
Gochenauer Alexandria
|
Jul/Aug 2018
Pg. 281-283
|
The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 1
Williams LaVonn
|
Jul/Aug 2018
Pg. 284-287
|
Quality Control: Water Activity Considerations for Beyond-use Dates
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 288-293
|
Basics of Compounding--Nonsterile: Compounding Self-emulsifying Drug Delivery Systems and Other Self-emulsifying Lipid Formulations, Part 2
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 294-300
|
Basics of Sterile Compounding: Criteria for Determining Beyond-use Dating
Martin Matt
|
Jul/Aug 2018
Pg. 303-312
|
Calculations
Stockton Shelly J
|
Jul/Aug 2018
Pg. 314
|
Anhydrous Medium-chain Triglycerides Gel
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 316
|
Budesonide 1-mg//10-mL Mucolox Oral Suspensions
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 317
|
Cinacalcet 5-mg/mL in Oral-Plus/Ora-Sweet Suspension
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 318
|
Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 319
|
Metronidazole Benzoate 70 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 320
|
Midazolam 1 mg/mL in SyrSpend SF or SyrSpend SF Cherry
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 321
|
Minoxidil 50 mg/mL in Espumil Foam Base
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 322
|
Oseltamivir Phosphate 15 mg/mL in SyrSpend SF
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 323
|
Pentoxifylline 5% in Dermabase
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 324
|
Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 325
|
Stability of Extemporaneously Prepared Sodium Benzoate Oral Suspension
Atkins Julia R, Lull Melinda E, Decker Andrew S, Hutchinson David J
|
Jul/Aug 2018
Pg. 326-328
|
Kinetics of Tetracaine Solvolysis in Propylene Glycol
McPherson Timothy B, Neumann William L, Goolsby Michael, Kolling William M
|
Jul/Aug 2018
Pg. 329-334
|
Long-term Physicochemical Stability of Concentrated Solutions of Noradrenaline Bitartrate in Polypropylene Syringes for Administration in the Intensive Care Unit
Lardinois Benjamin, Pector Johan, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin B, Hecq Jean-Daniel, Galanti Laurence M
|
Jul/Aug 2018
Pg. 335-339
|
Comparative Stability of Vitamin K1 Oral Liquids Prepared in Sterile Water for Injection and Stored in Amber Glass Bottles and Amber Plastic Syringes
Huffman Jessica, Brown Stacy, Lewis Paul, Lawson Sarah, Ogle Amanda, Peacock Gina
|
Jul/Aug 2018
Pg. 340-344
|
Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags
Breukels Oscar, van der Gronde Toon, Simons-Sanders Kathleen, Crul Mirjam
|
Jul/Aug 2018
Pg. 345-349
|
PreScription: Updating Formulations
Allen Loyd V Jr
|
Sep/Oct 2018
Pg. 356
|
Current Trends and Emerging Priorities in Compounded Preparations for Children
Parrish Richard H II
|
Sep/Oct 2018
Pg. 358-366
|
Certification of Powder-containment Hoods for Nonsterile Compounding
Mulder Kyle, Dozzi Raphael
|
Sep/Oct 2018
Pg. 369-384
|
Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations
Ashe Krystina, Baskett Dustin
|
Sep/Oct 2018
Pg. 387-398
|
Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1
Martin Matt
|
Sep/Oct 2018
Pg. 401-404
|
Calculations
Stockton Shelly J
|
Sep/Oct 2018
Pg. 406
|
Cysteamine 0.5% Ophthalmic Solution
Allen Loyd V Jr
|
Sep/Oct 2018
Pg. 408
|
Fluoxetine 50 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Sep/Oct 2018
Pg. 409
|
Pergolide Mesylate 0.2-mg/mL Oral Liquid, Veterinary
Allen Loyd V Jr
|
Sep/Oct 2018
Pg. 410
|
Torsemide 5 mg/mL in Ora-Plus:Ora-Sweet Suspension
Allen Loyd V Jr
|
Sep/Oct 2018
Pg. 411
|
Stability of Tranexamic Acid Mouth Rinse
Donnelly Ronald F
|
Sep/Oct 2018
Pg. 412-416
|
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags
Nalenz Heiko, Köpf Ellen, Dietel Elke
|
Sep/Oct 2018
Pg. 417-423
|
A Cold Process Preparation of Vetiveria zizanioides (L.) Nash Oil Lotions using Simulgel FL as an Emulsifier
Songkro Sarunyoo, Pengmak Somuredee, Seajung Pornyamol, Maneenuan Duangkhae, Kaewnopparat Nattha
|
Sep/Oct 2018
Pg. 424-432
|
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding
Zhao Fang, Dave Vivek S, Mar Mazin Z, Perri Jonathan R
|
Sep/Oct 2018
Pg. 433-439
|
PreScription: Standardized Concentrations: Pro or Con?
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 444
|
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
|
Nov/Dec 2018
Pg. 446-454
|
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome
Riepl Mike
|
Nov/Dec 2018
Pg. 456-465
|
Case Study: Absorption of Testosterone Cream via Scrotal Delivery
Needham Shawn, Needham Shane
|
Nov/Dec 2018
Pg. 466-468
|
Compounding from a Pharmacy Student's Perspective: Staying Competitive as a Compounding Pharmacy
Waldschmidt Ryan
|
Nov/Dec 2018
Pg. 471-473
|
Basics of Sterile Compounding. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 2
Martin Matt
|
Nov/Dec 2018
Pg. 475-478
|
Basics of Compounding: Vehicles for Compounded Oral Liquid Medications: A Review
Cutaia Kara, Chablani Lipika, Zhao Fang
|
Nov/Dec 2018
Pg. 480-489
|
Calculations
Stockton Shelly J
|
Nov/Dec 2018
Pg. 490
|
Clonazepam 0.2 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 492
|
Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 493
|
Enalapril Maleate 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 494
|
Hydrocortisone 2 mg/mL in Inorpha Suspension
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 495
|
Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 496
|
Prednisone 5 mg/mL ir Oral Mix Suspension
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 497
|
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Le Uyen Minh, Baltzley Sarah, AlGhananeem Abeer
|
Nov/Dec 2018
Pg. 498-503
|
Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase)
Ip Kendice, Shan Ashley, Yan Wei, Banov Daniel
|
Nov/Dec 2018
Pg. 504-511
|
Compounded Orodispersible Films with Natural Ingredients for Halitosis: A Clinical Experience
Apolinário Régis De Souza, Chaves Maria Das Graças Afonso Miranda, Gonçalves Hanny Reis Mockdeci, Martins Isadora Conde Ferreria, De Paula Renée Mazilão, Granato Ana Paula Alves, Polonini Hudson Caetano, Brandão Marcos Antônio Fernandes, Ferreira Anderson De Oliveira, Raposo Nádia Rezende Barbosa
|
Nov/Dec 2018
Pg. 512-515
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Errata
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 527
|
